BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 23321581)

  • 1. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.
    Reese AC; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
    Urology; 2015 Nov; 86(5):991-5. PubMed ID: 26335496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
    Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
    Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
    Ahmad AE; Richard PO; Leão R; Hajiha M; Martin LJ; Komisarenko M; Grewal R; Goldberg H; Salem S; Jain K; Oliaei A; Horyn I; Timilshina N; Zlotta A; Hamilton R; Kulkarni G; Fleshner N; Alibhaic SMH; Finelli A
    J Urol; 2020 Sep; 204(3):476-482. PubMed ID: 32259466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
    Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
    BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting prostatic biopsy Gleason sum under grading.
    Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
    J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.